Larvol Delta - Enrollment-is-complete-in-the-randomized-Phase-2-trial-of-casdozokitugtoripalimabbevacizumab-in-1L-uHCC-and-the-rst-data-readout-is-expected-2H-2026

casdozokitug (CHS-388) - Coherus Oncology

https://investors.coherus.com/news-releases/news-release-details/coherus-oncology-reports-second-quarter-2026-financial-results

Aug 5, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next